Followers | 9840 |
Posts | 260002 |
Boards Moderated | 4 |
Alias Born | 12/27/2006 |
Tuesday, July 14, 2020 5:29:31 PM
Link to Video - click here to watch the technical chart video
Recent ALDX News
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day • Business Wire • 04/25/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 • Business Wire • 04/18/2024 11:00:00 AM
- Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease • Business Wire • 03/28/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/07/2024 09:54:33 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 09:48:39 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/07/2024 09:40:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:06:42 PM
- Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference • Business Wire • 02/06/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/29/2024 10:25:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:00:30 PM
- Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases • Business Wire • 01/04/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:06:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 12:05:14 PM
- Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis • Business Wire • 12/19/2023 12:00:00 PM
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis • Business Wire • 12/18/2023 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 12:16:33 PM
- Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease • Business Wire • 11/27/2023 09:07:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/03/2023 08:43:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/03/2023 08:08:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 11:09:52 AM
- Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap • Business Wire • 11/01/2023 11:05:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 12:00:52 PM
- The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX) • PR Newswire (US) • 09/27/2023 09:45:00 AM
- The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX) • PR Newswire (US) • 09/26/2023 09:45:00 AM
- The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX) • PR Newswire (US) • 09/19/2023 09:45:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM